Monurol Side Effects

Generic Name: fosfomycin

Note: This page contains information about the side effects of fosfomycin. Some of the dosage forms included on this document may not apply to the brand name Monurol.

Not all side effects for Monurol may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to fosfomycin: oral powder for solution

In addition to its needed effects, some unwanted effects may be caused by fosfomycin (the active ingredient contained in Monurol). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking fosfomycin:

  • Blood in the urine
  • burning while urinating
  • cough or hoarseness
  • difficult or painful urination
  • fever or chills
  • lower back or side pain
  • painful or difficult urination
Incidence not known
  • Abdominal or stomach pain or tenderness
  • black, tarry stools
  • bloating
  • chest pain
  • clay-colored stools
  • constipation
  • dark urine
  • diarrhea
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • headache
  • hives
  • itching
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • light-colored stools
  • loss of appetite
  • nausea or vomiting
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rash
  • severe abdominal or stomach cramps and pain
  • shortness of breath
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen or painful glands
  • tightness in the chest
  • unpleasant breath odor
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting of blood
  • watery and severe diarrhea, which may also be bloody
  • wheezing
  • worsening of asthma
  • yellow eyes or skin

Some of the side effects that can occur with fosfomycin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Itching of the vagina or genital area
  • pain during sexual intercourse
  • thick, white vaginal discharge with no odor or with a mild odor
Less common
  • Acid or sour stomach
  • back pain
  • belching
  • body aches or pain
  • congestion
  • dryness or soreness of the throat
  • heartburn
  • heavy bleeding
  • indigestion
  • lack or loss of strength
  • pain
  • painful menstruation
  • runny or stuffy nose
  • skin rash
  • sneezing
  • sore throat
  • stomach discomfort or upset
  • tender, swollen glands in the neck
  • trouble with swallowing
  • voice changes
  • weakness
  • Abnormal stools
  • absent missed or irregular menstrual periods
  • blindness
  • blue-yellow color blindness
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • decreased vision
  • difficulty with moving
  • dry mouth
  • excess air or gas in the stomach or intestines
  • eye pain
  • full feeling
  • headache, severe and throbbing
  • joint pain
  • loss of appetite
  • muscle aching or cramping
  • muscle pains or stiffness
  • nervousness
  • passing gas
  • sleepiness or unusual drowsiness
  • sleeplessness
  • stopping of menstrual bleeding
  • swollen joints
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • trouble sleeping
  • unable to sleep
  • weight loss
Incidence not known
  • Hearing loss

For Healthcare Professionals

Applies to fosfomycin: oral powder for reconstitution


Very common (10% or more): Diarrhea (up to 10.4%)
Common (1% to 10%): Nausea, abdominal pain, dyspepsia, retching, stomach ache
Uncommon (0.1% to 1%): Abnormal stools, constipation, dry mouth, flatulence, vomiting
Frequency not reported: Pseudomembranous colitis
Postmarketing reports: Toxic megacolon

Nervous system

Very common (10% or more): Headache (up to 10.3%)
Common (1% to 10%): Dizziness
Uncommon (0.1% to 1%): Dysgeusia, paresthesia, migraine, somnolence, vertigo
Postmarketing reports: Hearing loss


Common (1% to 10%): Vaginitis, dysmenorrhea
Uncommon (0.1% to 1%): Hematuria, dysuria, menstrual disorder


Common (1% to 10%): Pain, asthenia, injection site phlebitis
Uncommon (0.1% to 1%): Fatigue, infection, ear disorder, fever, influenza syndrome
Frequency not reported: Facial edema


Very rare (less than 0.01%): Anaphylactic shock
Postmarketing reports: Anaphylaxis


Common (1% to 10%): Rhinitis, pharyngitis
Uncommon (0.1% to 1%): Dyspnea
Frequency not reported: Asthmatic attack
Postmarketing reports: Exacerbation of asthma


Angioedema has also been reported during postmarketing experience.

Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus, skin disorder
Frequency not reported: Angioedema, urticaria


Common (1% to 10%): Back pain
Uncommon (0.1% to 1%): Myalgia


Increased alkaline phosphatase was generally transient and not clinically significant.

Uncommon (0.1% to 1%): Anorexia, decreased appetite, hypernatremia and/or hypokalemia, increased alkaline phosphatase


Increased eosinophil count, increased or decreased white blood cell count, increased and decreased platelet count, decreased hematocrit, and decreased hemoglobin were generally transient and not clinically significant.

Aplastic anemia has also been reported during postmarketing experience.

Uncommon (0.1% to 1%): Lymphadenopathy
Rare (0.01% to 0.1%): Aplastic anemia, eosinophilia
Frequency not reported: Agranulocytosis, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia, increased eosinophil count, increased or decreased white blood cell count, increased and decreased platelet count, decreased hematocrit, decreased hemoglobin


Uncommon (0.1% to 1%): Increased ALT, increased AST
Very rare (less than 0.01%): Fatty liver
Frequency not reported: Increased bilirubin, hepatitis, cholestatic hepatitis, icterus
Postmarketing reports: Cholestatic jaundice, hepatic necrosis

Fatty liver was completely reversible after IV fosfomycin was discontinued.

Increased bilirubin, increased ALT, and increased AST were generally transient and not clinically significant.


Uncommon (0.1% to 1%): Tachycardia


Uncommon (0.1% to 1%): Insomnia, nervousness
Frequency not reported: Confusion


Very rare (less than 0.01%): Visual impairment
Frequency not reported: Unilateral optic neuritis

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.